Zacks22d agoneutral
Eli Lilly (LLY) Rises Higher Than Market: Key FactsEli Lilly (LLY) closed the most recent trading day at $1, moving +2.09% from the previous trading session.
Notícias
Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
235last 24h
1425last 7d
239● bullish (7d)
156● bearish (7d)
205publishers
Zacks23d agobullish
INCY Q2 Earnings & Revenues Beat on Higher Sales, '26 View RaisedIncyte tops Q2 earnings and revenue estimates as Jakafi and Opzelura sales surged, prompting the company to raise its 2026 revenue outlook.
Motley Fool23d agoneutral
Eli Lilly Just Made a $2.8 Billion Bet That Goes Beyond GLP-1 DrugsThe company isn't resting on its laurels.
Zacks23d agoneutral
Here's How LLY's Non-GLP-1 Portfolio Is Poised Ahead of Q2 EarningsEli Lilly's expanding oncology and newer medicine portfolio is set to play a pivotal role in its Q2 earnings alongside its blockbuster GLP-1 franchise.
StockStory23d agoneutral
3 Quality Compounders to Own for DecadesA quality compounder is a business that not only sports durable competitive advantages but also builds on its success by consistently reinvesting its profits at high returns.
Simply Wall St.23d agoneutral
Eli Lilly (LLY) Stock Gets Fair Value Bump As Analysts Lift Targets On GLP1 OutlookAnalysts have been lifting Eli Lilly price targets, with recent valuation work for the stock pointing to fair value of US$1,270.37 compared with the prior US$1,243.43 anchor. The shift lines up with a more constructive Wall Street stance as firms reassess the obesity and diabetes portfolio, retatrutide data, and Q2 earnings setup, with bullish targets clustering between roughly US$1,232 and US$1,600. Ahead, you will see how this evolving narrative, both bullish and cautious, can shape how you...
Barrons.com24d agobullish
Leah Bennett: Where to Invest After the AI-Chip Stock SurgeThe chief investment strategist at Concurrent Asset Management shares her top investment picks right now.
TheStreet24d agoneutral
Goldman Sachs sees writing on the wall for Eli Lilly stockEli Lilly (LLY) stock has turned into one of the best comeback trades of 2026. Shares closed at $1,196.03 on July 24, up nearly 11% year to date after a rough start dragged the stock below $900 in the spring. Lilly shares have climbed about 39% since the company's first-quarter report, according to ...
Insider Monkey26d agoneutral
Jim Cramer Wants Novo Nordisk A/S (NYSE:NVO) To Compete With Eli Lilly In The Market & Not The CourtsNovo Nordisk A/S (NYSE:NVO) was at the center of media coverage as it sued rival weight loss drug manufacturer Eli Lilly on Tuesday. The firm claimed that Lilly had run misleading advertisements about its weight loss drug when it came to touting their superior performance over Novo Nordisk A/S (NYSE:NVO)’s products. It claimed that Lilly […]
Reuters Videos26d agoneutralVIDEO
Nasdaq lags on angst over AI spending ahead of earnings reports<body><p>STORY: U.S. stocks ended mixed on Friday, with the Dow gaining just under half a percent, the S&P 500 virtually flat and the tech-heavy Nasdaq sliding nearly two-thirds of a percent.</p><p>The S&P 500 technology index underperformed the broader market as chip stocks fell, with Intel dropping nearly 8% despite forecasting quarterly profit and revenue above Wall Street estimates.</p><p>Enthusiasm for the AI trade weakened after Alphabet's announcement earlier this week of a plan to hike capital spending even as it burns cash.</p><p>Richard Reyle, chief investment officer at Questar Capital Partners, said that as a result investors are rotating into what he called "safer parts of the market."</p><p>"Pharmaceuticals have been flying, and that's been, I think, where we see the rotation of the market right now. [FLASH] You look at the iShares, pharmaceutical fund, it's big components that are J&J and Eli Lilly, they're at all-time highs. And they're still relatively not super expensive stocks. So I think that's a place that can be bought and held. And of course, energy. Exxon's going to announce earnings next week. I bet they're going to be a blockbuster and they're going to continue to be because they make money at $60 a barrel. At $100 a barrel, forget about it. They do very well."</p><p>The S&P 500 real estate sector also outperformed during the session. Its leading gainer was Digital Realty Trust, which rallied 11% after it raised its full-year forecast for funds from operations.</p><p>Among other gainers, shares of SLB climbed 11% after the oilfield services firm beat expectations for second-quarter profit.</p><p>Investors now turn their attention to quarterly results next week from Magnificent 7 megacaps Microsoft, Amazon, Meta and Apple.</p></body>
MT Newswires26d agoneutral
Sector Update: Healthcare Stocks Higher Late AfternoonHealthcare stocks rose late Friday afternoon, with the NYSE Healthcare Index up 0.6% and the State S
GuruFocus.com26d agobullish
Scribe Therapeutics Soars 67% After $128.7 Million Upsized IPOGene-editing biotech debuts at $25, backed by Sanofi and Eli Lilly, with a roughly $440.3 million valuation.
24/7 Wall St.26d agoneutral
This Catalyst Makes Eli Lilly a Top Growth Stock in 2026Eli Lilly just won FDA clearance for an oral GLP-1 that targets over one billion potential patients worldwide, and the stock has barely moved. Here is whether that disconnect signals a buying opportunity or a trap.
Motley Fool26d agoneutral
Why Is Novo Nordisk Suing Eli Lilly, and What Does it Mean for Investors?Novo Nordisk is accusing Eli Lilly of deceptive advertising about GLP-1 drugs.
Simply Wall St.26d agoneutral
Novo Nordisk (CPSE:NOVO B) Sues Eli Lilly Over GLP 1 Drug AdvertisingNovo Nordisk (CPSE:NOVO B) has filed a federal lawsuit against Eli Lilly over alleged false and misleading advertising of GLP-1 obesity and diabetes drugs. The company argues that Eli Lilly’s ads misrepresent clinical comparisons and risk misleading consumers and healthcare professionals. The case highlights rising tensions as both companies compete in the fast growing market for GLP-1 based obesity and diabetes treatments. Novo Nordisk is a major player in diabetes and obesity treatments,...
Bloomberg27d agobullish
Eli Lilly-Backed Scribe Therapeutics Jumps 67% After Upsized IPO(Bloomberg) -- Scribe Therapeutics Inc., a clinical-stage developer of gene therapies for heart diseases, surged 67% on Friday after raising $128.7 million in an upsized initial public offering.Most Read from BloombergRetina Chip Designed to Restore Sight to Go on Sale in EuropeHegseth Turns to UNC, Virginia Tech After Dropping Ivy LeagueApple Plans Overhaul of MacBooks, iMac in Push to Meet AI DemandTrump Rebuilds Tariffs With New Levies on 60 EconomiesSpaceX Turns Away Falcon Customers in Majo
Investor's Business Daily27d agobullish
Eli Lilly Stock In A Buy Zone, Set To Ride The Peptide WaveEli Lilly stock hit an all-time high of 1,249.50 before pulling back into a buy zone above a pivot of 1,133.95.
MT Newswires27d agoneutral
Update: Market Chatter: Novo Nordisk Seeks Immediate Court Order Against Lilly's Weight-Loss Drug Ads(Updates with responses from Novo Nordisk and Eli Lilly in the fourth and fifth paragraphs.) Novo
Zacks27d agobullish
Incyte Gears Up to Report Q2 Earnings: Is a Beat Around the Corner?INCY heads into Q2 earnings with strong Jakafi demand, Opzelura momentum and rising royalties, fueling expectations for an earnings beat.
TheStreet27d agoneutral
Ozempic maker takes biggest rival to court over weight-loss drug adsNovo Nordisk, the maker of Ozempic, is suing Eli Lilly over advertisements comparing some of their biggest-selling drugs. The ads compare Lilly’s Zepbound with Novo’s Wegovy, and Novo argues they give consumers a misleading picture of how the blockbuster weight-loss drugs stack up. At the center of ...
Zacks27d agobullish
LLY's Retatrutide Nears 2027 Filing With Two More Phase III WinsEli Lilly's retatrutide meets the primary endpoint in the phase III TRIUMPH-2 & TRIUMPH-3 studies, supporting planned regulatory submissions for obesity in 2027.
Barrons.com27d agoneutral
As Lilly and Novo Clash in Court, Wall Street Is Eyeing This Bigger PrizeThe legal battle between Novo Nordisk and Eli Lilly is escalating, but analysts are more focused on developments in the lab.